Patents by Inventor Kouji Matsushima
Kouji Matsushima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11919932Abstract: Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.Type: GrantFiled: January 3, 2023Date of Patent: March 5, 2024Assignees: THE UNIVERSITY OF TOKYO, ONO PHARMACEUTICAL CO., LTD., TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Kouji Matsushima, Satoshi Ueha, Shungo Deshimaru, Chang-Yu Chen, Shoji Yokochi, Yoshiro Ishiwata, Shiro Shibayama
-
Publication number: 20230220022Abstract: Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.Type: ApplicationFiled: January 3, 2023Publication date: July 13, 2023Applicants: The University of Tokyo, ONO PHARMACEUTICAL CO., LTD., TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Kouji MATSUSHIMA, Satoshi UEHA, Shungo DESHIMARU, Chang-Yu CHEN, Shoji YOKOCHI, Yoshiro ISHIWATA, Shiro SHIBAYAMA
-
Patent number: 11572393Abstract: Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.Type: GrantFiled: March 7, 2019Date of Patent: February 7, 2023Assignees: THE UNIVERSITY OF TOKYO, ONO PHARMACEUTICAL CO., LTD., TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Kouji Matsushima, Satoshi Ueha, Shungo Deshimaru, Chang-Yu Chen, Shoji Yokochi, Yoshiro Ishiwata, Shiro Shibayama
-
Publication number: 20220356462Abstract: A nucleic acid amplification method using a solid-phase carrier according to the present invention comprises: capturing a target nucleic acid comprising mRNA on a solid-phase carrier; carrying out complementary-strand synthesis on the solid phase; carrying out exonuclease treatment to degrade and remove unreacted target- capturing nucleic acid on the solid phase; and then carrying out mRNA degradation and homopolymer addition by TdT reaction in the presence of a chain-terminating nucleotide triphosphate. According to the method of the present invention, cDNA can be stably and highly efficiently amplified even from a small amount of sample even in cases where the ratio of the amount of enzyme to the DNA substrate on the solid phase is excessive, where the reaction time is excessive, and/or where reagents show lot-to-lot variation.Type: ApplicationFiled: July 10, 2020Publication date: November 10, 2022Applicant: TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Kouji MATSUSHIMA, Satoshi UEHA, Shigeyuki SHICHINO, Satoru ITO, Hiroyasu AOKI
-
Publication number: 20220313647Abstract: Disclosed is a novel measure that is effective in therapy etc. of psychiatric or neurological disorders or symptoms, such as anxiety or depressive disorders, and is unlikely to cause problems such as dependence and adverse effects and is highly safe. The present invention provides an agent for treating, preventing, or ameliorating psychiatric or neurological disorders or symptoms, wherein the agent contains any of the followings as an active ingredient: (1) disulfiram, (2) a metal complex of diethyldithiocarbamate, (3) a disulfide capable of generating diethyldithiocarbamate in the body, (4) a pharmaceutically acceptable salt of (1), (2), or (3), and (5) a solvate of (1), (2), (3), or (4).Type: ApplicationFiled: September 25, 2020Publication date: October 6, 2022Applicant: TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Akiyoshi SAITOH, Yuya TERASHIMA, Kouji MATSUSHIMA, Yoshitake SANO
-
Patent number: 11193172Abstract: Novel means that enables prediction of prognosis of a patient with cancer or inflammatory disease is disclosed. In the method for prediction of prognosis of a patient with cancer or inflammatory disease according to the present invention, the expression level of the FROUNT gene in a sample collected from the patient is measured. Since FROUNT is a poor prognostic factor, the lower the expression level of the FROUNT gene is, the better the prognosis in the patient is predicted to be. Or, the expression level of the CC chemokine receptor/ligand gene in a sample collected from the patient is measured. Since the CC chemokine receptor/ligand gene such as CCR2 or CCR5 is a good prognostic factor, the higher the expression level of the CC chemokine receptor/ligand gene is, the better the prognosis in the patient is predicted to be.Type: GrantFiled: January 8, 2016Date of Patent: December 7, 2021Assignee: TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Yuya Terashima, Kouji Matsushima, Etsuko Toda, Mikiya Otsuji, Meiji Itakura
-
Patent number: 11168137Abstract: Disclosed is a means for reducing side effects of an immune checkpoint regulator that is used as an anticancer drug or the like. A side-effect reducing agent according to the present invention comprises as an effective ingredient an anti-CD4 antibody having a high cytotoxic activity, or an anti-CD4 antibody or antigen-binding fragment thereof which antibody or fragment comprises a cytotoxic component bound thereto. The anti-CD4 antibody is a human-type chimeric antibody, humanized antibody or human antibody against human CD4. The immune checkpoint regulator may be, for example, an anti-PD-L1 antibody, an antagonistic anti-CTLA-4 antibody, or an agonistic anti-OX40 antibody.Type: GrantFiled: June 10, 2015Date of Patent: November 9, 2021Assignees: IDAC THERANOSTICS, INC., THE UNIVERSITY OF TOKYOInventors: Satoru Ito, Shoji Yokochi, Kouji Matsushima, Satoshi Ueha, Yoshiro Ishiwata
-
Publication number: 20210220320Abstract: Disclosed is a novel means that is effective for analgesia or sedation. The analgesic or sedative agent of the present invention comprises, an active component, disulfiram, a metal complex of diethyldithiocarbamate, a disulfide capable of generating diethyldithiocarbamate in the body, a pharmaceutically acceptable salt of any of these compounds, or a solvate of any of these compounds or salts thereof. Disulfiram and the above-described metal complex are known to have anticancer and anti-inflammatory effects. The agent of the present invention can exert multiple therapeutic benefits such as anticancer, anti-inflammatory, analgesic, and sedative effects, in cancer patients.Type: ApplicationFiled: January 31, 2019Publication date: July 22, 2021Applicant: THE UNIVERSITY OF TOKYOInventors: Yuya TERASHIMA, Etsuko TODA, Kouji MATSUSHIMA
-
Publication number: 20200407408Abstract: Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.Type: ApplicationFiled: March 7, 2019Publication date: December 31, 2020Applicants: The University of Tokyo, ONO PHARMACEUTICAL CO., LTD., TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Kouji MATSUSHIMA, Satoshi UEHA, Shungo DESHIMARU, Chang-Yu CHEN, Shoji YOKOCHI, Yoshiro ISHIWATA, Shiro SHIBAYAMA
-
Patent number: 10746726Abstract: Means that enables monitoring of an anticancer effect of an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint is disclosed. The method for testing a therapeutic effect of a cancer therapy of the present invention is a method for testing a therapeutic effect of an anticancer drug comprising as an effective ingredient an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint, which method comprises investigation of expression of (1) at least one immune checkpoint receptor, (2) CD8, and (3) at least one cell surface molecule selected from the group consisting of CD44 and CD45RO, on T cells using a sample derived from a patient who received the anticancer drug. Induction of a T cell population which is positive for the immune checkpoint molecule (1) and positive for CD8, and which shows high expression of CD44 and/or high expression of CD45RO, indicates that said anticancer drug is producing a therapeutic effect in said patient.Type: GrantFiled: December 2, 2015Date of Patent: August 18, 2020Assignees: THE UNIVERSITY OF TOKYO, IDAC THERANOSTICS, INC.Inventors: Kouji Matsushima, Satoshi Ueha, Satoru Ito, Shoji Yokochi, Yoshiro Ishiwata
-
Publication number: 20200253896Abstract: An agent according to the present invention comprises as an effective component any of (1) disulfiram, diethyldithiocarbamate, or a metal complex of diethyldithiocarbamate; (2) a pharmaceutically acceptable salt of (1); or (3) a solvate of (1) or (2), and is used for inhibition of interaction between CR2B or CCR5 and FROUNT protein, inhibition of macrophages, control of cells constituting a cancer microenvironment or inflammatory microenvironment, or enhancement of anticancer activity of an anticancer drug. It is also possible to provide a compound with a reduced side effect and an increased pharmacological effect by identifying a disulfiram derivative having a lower aldehyde dehydrogenase-inhibiting activity and a higher FROUNT-inhibiting activity among derivatives prepared by structural modification of disulfiram.Type: ApplicationFiled: February 20, 2020Publication date: August 13, 2020Applicant: The University of TokyoInventors: Yuya TERASHIMA, Kouji MATSUSHIMA, Etsuko TODA, Hiroaki TERASAWA, Sosuke YOSHINAGA
-
Patent number: 10738352Abstract: The present invention relates to a method of analyzing a composition of nucleic acids derived from a single cell using a microplate including a plurality of reaction wells, the microplate having one bead arranged in one reaction well, the one bead having bound thereto a plurality of molecules of single-stranded oligonucleotides, the single-stranded oligonucleotides each having a nucleic acid capture sequence exposed at the 3? end and a barcode sequence on the 5? side of the nucleic acid capture sequence, the barcode sequence including a base sequence that differs from bead to bead.Type: GrantFiled: April 7, 2015Date of Patent: August 11, 2020Assignee: IDAC THERANOSTICS, INC.Inventors: Shin-ichi Hashimoto, Shuichi Kaneko, Kouji Matsushima
-
Patent number: 10722480Abstract: An agent according to the present invention comprises as an effective component any of (1) disulfiram, diethyldithiocarbamate, or a metal complex of diethyldithiocarbamate; (2) a pharmaceutically acceptable salt of (1); or (3) a solvate of (1) or (2), and is used for inhibition of interaction between CR2B or CCR5 and FROUNT protein, inhibition of macrophages, control of cells constituting a cancer microenvironment or inflammatory microenvironment, or enhancement of anticancer activity of an anticancer drug. It is also possible to provide a compound with a reduced side effect and an increased pharmacological effect by identifying a disulfiram derivative having a lower aldehyde dehydrogenase-inhibiting activity and a higher FROUNT-inhibiting activity among derivatives prepared by structural modification of disulfiram.Type: GrantFiled: January 6, 2016Date of Patent: July 28, 2020Assignee: TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Yuya Terashima, Kouji Matsushima, Etsuko Toda, Hiroaki Terasawa, Sosuke Yoshinaga
-
Patent number: 10300115Abstract: The instant invention provides methods and compositions for modulation of the immune system. Specifically, the present disclosure provides methods and compositions for increasing T cell mediated immune response useful in the treatment of cancer and chronic infection.Type: GrantFiled: January 11, 2017Date of Patent: May 28, 2019Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Arya Biragyn, Kouji Matsushima, Dolgor Baatar
-
Publication number: 20190125867Abstract: Disclosed is a novel means effective for treatment, metastasis-inhibition, and recurrence-inhibition of human solid cancer. A therapeutic agent for solid cancer according to the present invention comprises as an effective ingredient an anti-CD4 antibody having a high cytotoxic activity, or an anti-CD4 antibody or antigen-binding fragment thereof which antibody or fragment comprises a cytotoxic component bound thereto. Said anti-CD4 antibody is a human-type chimeric antibody, humanized antibody or human antibody against human CD4. The therapeutic agent of the present invention produces still higher effects by combined use with antagonist or agonist against immune checkpoint molecule, small molecule anticancer agents, or the like. The therapeutic agent is also effective in suppressing recurrence and metastasis of solid cancer.Type: ApplicationFiled: December 27, 2018Publication date: May 2, 2019Applicants: IDAC THERANOSTICS, INC., THE UNIVERSITY OF TOKYOInventors: Satoru ITO, Shoji YOKOCHI, Kouji MATSUSHIMA, Satoshi UEHA, Yoshiro ISHIWATA
-
Publication number: 20180237860Abstract: Novel means that enables prediction of prognosis of a patient with cancer or inflammatory disease is disclosed. In the method for prediction of prognosis of a patient with cancer or inflammatory disease according to the present invention, the expression level of the FROUNT gene in a sample collected from the patient is measured. Since FROUNT is a poor prognostic factor, the lower the expression level of the FROUNT gene is, the better the prognosis in the patient is predicted to be. Or, the expression level of the CC chemokine receptor/ligand gene in a sample collected from the patient is measured. Since the CC chemokine receptor/ligand gene such as CCR2 or CCR5 is a good prognostic factor, the higher the expression level of the CC chemokine receptor/ligand gene is, the better the prognosis in the patient is predicted to be.Type: ApplicationFiled: January 8, 2016Publication date: August 23, 2018Applicants: The University of Tokyo, CHIBA PREFECTUREInventors: Yuya TERASHIMA, Kouji MATSUSHIMA, Etsuko TODA, Mikiya OTSUJI, Meiji ITAKURA
-
Patent number: 9895331Abstract: An object of the present invention is to provide a preventive and/or therapeutic agent for radiation damage that has a novel mechanism of action and can prevent and alleviate a wide range of symptoms of radiation damage for which no therapeutic measures have been available so far, and moreover, is highly safe to humans. A preventive and/or therapeutic agent for radiation damage comprising a compound represented by the following formula (I) such as 5-aminolevulinic acid (5-ALA) or a salt thereof as an active ingredient can be used to improve the survival rate, improve body weight reduction, and alleviate hematopoietic disorder: (wherein R1 represents a hydrogen atom or an acyl group; and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group).Type: GrantFiled: July 11, 2013Date of Patent: February 20, 2018Assignees: The University of Tokyo, SBI Pharmaceuticals Co., Ltd.Inventors: Tohru Tanaka, Motowo Nakajima, Fuminori Abe, Hidenori Ito, Kiwamu Takahashi, Kouji Matsushima, Satoshi Ueha, Jun Abe
-
Publication number: 20180000755Abstract: An agent according to the present invention comprises as an effective component any of (1) disulfiram, diethyldithiocarbamate, or a metal complex of diethyldithiocarbamate; (2) a pharmaceutically acceptable salt of (1); or (3) a solvate of (1) or (2), and is used for inhibition of interaction between CR2B or CCR5 and FROUNT protein, inhibition of macrophages, control of cells constituting a cancer microenvironment or inflammatory microenvironment, or enhancement of anticancer activity of an anticancer drug. It is also possible to provide a compound with a reduced side effect and an increased pharmacological effect by identifying a disulfiram derivative having a lower aldehyde dehydrogenase-inhibiting activity and a higher FROUNT-inhibiting activity among derivatives prepared by structural modification of disulfiram.Type: ApplicationFiled: January 6, 2016Publication date: January 4, 2018Applicant: The University of TokyoInventors: Yuya TERASHIMA, Kouji MATSUSHIMA, Etsuko TODA, Hiroaki TERASAWA, Sosuke YOSHINAGA
-
Publication number: 20170328887Abstract: Means that enables monitoring of an anticancer effect of an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint is disclosed. The method for testing a therapeutic effect of a cancer therapy of the present invention is a method for testing a therapeutic effect of an anticancer drug comprising as an effective ingredient an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint, which method comprises investigation of expression of (1) at least one immune checkpoint receptor, (2) CD8, and (3) at least one cell surface molecule selected from the group consisting of CD44 and CD45RO, on T cells using a sample derived from a patient who received the anticancer drug. Induction of a T cell population which is positive for the immune checkpoint molecule (1) and positive for CD8, and which shows high expression of CD44 and/or high expression of CD45RO, indicates that said anticancer drug is producing a therapeutic effect in said patient.Type: ApplicationFiled: December 2, 2015Publication date: November 16, 2017Applicants: The University of Tokyo, IDAC Theranostics, Inc.Inventors: Kouji MATSUSHIMA, Satoshi UEHA, Satoru ITO, Shoji YOKOCHI, Yoshiro ISHIWATA
-
Publication number: 20170165364Abstract: Disclosed is a novel means effective for treatment, metastasis-inhibition, and recurrence-inhibition of human solid cancer. A therapeutic agent for solid cancer according to the present invention comprises as an effective ingredient an anti-CD4 antibody having a high cytotoxic activity, or an anti-CD4 antibody or antigen-binding fragment thereof which antibody or fragment comprises a cytotoxic component bound thereto. Said anti-CD4 antibody is a human-type chimeric antibody, humanized antibody or human antibody against human CD4. The therapeutic agent of the present invention produces still higher effects by combined use with antagonist or agonist against immune checkpoint molecule, small molecule anticancer agents, or the like. The therapeutic agent is also effective in suppressing recurrence and metastasis of solid cancer.Type: ApplicationFiled: February 9, 2015Publication date: June 15, 2017Applicants: IDAC THERANOSTICS, INC., THE UNIVERSITY OF TOKYOInventors: Satoru ITO, Shoji YOKOCHI, Kouji MATSUSHIMA, Satoshi UEHA, Yoshiro ISHIWATA